Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Fineline Cube Mar 16, 2026
Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Fineline Cube Mar 16, 2026
Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Fineline Cube Mar 16, 2026
Company Medical Device

Zai Lab and Novocure’s TTFields Device Shows Survival Benefit in Lung Cancer Study

Fineline Cube Jan 6, 2023

Shares in Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) and its partner Novocure...

Company Drug

Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133

Fineline Cube Jan 6, 2023

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...

Company Deals

Kactus Biosystems Partners with Bioheng for Cell Therapy Raw Materials

Fineline Cube Jan 6, 2023

Shanghai-based Kactus Biosystems, a firm specializing in target proteins and raw enzymes, has announced a...

Company Deals

Immune-Onc Therapeutics Completes $131 Million Series B Financing

Fineline Cube Jan 6, 2023

US-headquartered Immune-Onc Therapeutics, Inc. has announced the successful completion of a Series B financing round...

Company Drug

Henlius Completes First Dosing in Global Phase III Study for HanSiZhuang in LS-SCLC

Fineline Cube Jan 6, 2023

Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...

Company Deals

Singular Medical Secures Series B+ Funding for Cardiac Device Development

Fineline Cube Jan 6, 2023

Singular Medical, a Suzhou-based maker of cardiac rhythm and heart failure devices, has reportedly raised...

Company Drug

Boehringer Ingelheim Enrolls First Patient in Phase II/III Study for BI 907828

Fineline Cube Jan 6, 2023

German pharmaceutical giant Boehringer Ingelheim has announced the enrollment of the first patient in the...

Company Drug

Vcanbio’s Stem Cell Therapy VUM02 Accepted for Clinical Trial Review

Fineline Cube Jan 6, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...

Company Drug

CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data

Fineline Cube Jan 6, 2023

China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...

Company Deals

Mindray Partners with BOMImed for Exclusive Canadian Sales and Service

Fineline Cube Jan 6, 2023

China-based medical device giant Mindray’s North American unit has announced a partnership with Canadian biomedical...

Company Deals

Simnova Partners with Orna Therapeutics for In Situ CAR Therapies

Fineline Cube Jan 6, 2023

Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has announced a...

Company

Aurisco Partners with Cytiva to Build Oligonucleotide Production Plant

Fineline Cube Jan 6, 2023

China-based contract development and manufacturing organization (CDMO) Aurisco Pharmaceutical Co., Ltd has revealed plans to...

Company Drug

Jiangsu Aidea’s ACC007 Approved by NMPA for HIV-1 Treatment

Fineline Cube Jan 5, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that its Category 1 compound...

Company Deals

WuXi Biologics and GSK Ink Licensing Agreement for T-Cell Engaging Antibodies

Fineline Cube Jan 5, 2023

China-based WuXi Biologics (HKG: 2269) has announced a licensing agreement with GSK plc (NYSE: GSK),...

Company Deals

Antengene Acquires Full Rights to Calithera’s CD73 Inhibitor CB-708

Fineline Cube Jan 5, 2023

China-based Antengene Corporation Ltd (HKG: 6996) has unveiled a transfer agreement with US-headquartered Calithera Biosciences...

Company Drug

Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA

Fineline Cube Jan 5, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...

Company Deals

Duality Biologics Licenses ADC Platform to Denmark’s Adcendo for Mesenchymal Tumor Program

Fineline Cube Jan 5, 2023

Duality Biologics, a developer of novel modality drugs operating in the United States and China,...

Policy / Regulatory

NMPA Strengthens Oversight of COVID-19 Drugs and Home Treatment Guidelines

Fineline Cube Jan 5, 2023

The National Medical Products Administration (NMPA) has released a notification aimed at enhancing the quality...

Company Medical Device

NMPA Approves Chinabridge’s ECMO Equipment for Emergency Use

Fineline Cube Jan 5, 2023

The National Medical Products Administration (NMPA) has approved Chinabridge (Shenzhen) Medical Technology Co., Ltd’s extracorporeal...

Company Drug

EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer

Fineline Cube Jan 5, 2023

EOC Pharma, a biotech company operating in the US and China, has announced that its...

Posts pagination

1 … 546 547 548 … 634

Recent updates

  • Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine
  • 3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market
  • Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas
  • China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL
  • Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Company Drug

Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas

Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.